Takeda settled the Actos patent suit with MYL, WPI, and Ranbaxy—the first-filer challengers—on essentially the same terms as the authorized-generic settlement with Teva—i.e. the above companies will be able to market their generics in the US starting in Aug 2012:
Takeda also settled with the Actos patent challengers who were not first-filers, enabling them to launch US generics in Feb 2013, after the first-filer companies complete 180 days of co-exclusivity. The non-first-filers are Alphapharm (now part of MYL), Sandoz, Torrent, Dr. Reddy's, Wockhardt, Synthon, Breckenridge, and Aurobindo.
News 
Market Data 
Discover 
AI
